Use of concomitant glycoprotein IIb/IIIa inhibitors with catheter-directed peripheral arterial thrombolysis

Journal of Vascular and Interventional Radiology

Volumn 15, Issue 6, 2004, Pages 543-546

  Ouriel, Kenneth ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; RETEPLASE; TENECTEPLASE; THROMBIN;

CATHETERIZATION; CLINICAL TRIAL; DRUG USE; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; INHIBITION KINETICS; INTERVENTIONAL RADIOLOGY; NOTE; NUTRIENT; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOSIS; TREATMENT OUTCOME; UNITED KINGDOM; VASCULAR SURGERY;

EID: 2942562032     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.00000127892.92928.74     Document Type: Note

References (30)

1. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exper Med 1933; 58:485.
2. Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci. II. J Exper Med 1934; 60:255.
3. Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. J Clin Invest 1949; 28:173.
4. Tillett WS, Johnson AJ, McCarty WR. The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients. J Clin Invest 1955; 34:169-185.
5. Cliffton EE, Grunnet M. Investigations of intravenous plasmin (fibrinolysin) in humans. Circulation 1956; 14:919.
6. Cliffton EE. The use of plasmin in humans. Ann N Y Acad Sci 1957; 68:209-229.
7. Dotter CT, Rösch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111:31-37.
8. McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. AJR Am J Roentgenol 1985; 144:769-775.
9. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994; 19:1021-1030.
10. Anonymous. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg 1994; 220:251-266.
11. Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators J Vasc Surg 1996; 23:64-73.
12. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998; 338:1105-1111.
13. Ouriel K. Urokinase and the US Food and Drug Administration. J Vasc Surg 1999; 30:957-958.
14. Drescher P, Crain MR, Rilling WS. Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study. J Vasc Interv Radiol 2002; 13:37-43.
15. McNamara TO, Dong P, Chen J, et al. Bleeding complications associated with the use of rt-PA versus r-PA for peripheral arterial and venous thromboembolic occlusions. Tech Vasc Interv Radiol 2001; 4:92-98.
16. Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. J Vasc Surg 1996; 23:64-73.
17. Ouriel K, Katzen B, Mewissen M, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol 2000; 11:849-854.
18. Ouriel K, Kandarpa K, Schuerr DM, et al. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial. J Vasc Interv Radiol 1999; 10:1083-1091.
19. Ouriel K, Donayre C, Shortell CK, et al. The hemodynamics of thrombus formation in arteries. J Vasc Surg 1991; 14:757-762.
20. Fitzgerald DJ, Catella F, Roy L, et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. N Engl J Med 1988; 77:142-150.
21. Collet JP, Montalescot G, Lesty C, et al. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res 2002; 90:428-434.
22. Merlini PA, Bauer KA, Oltrona L, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995; 25:203-209.
23. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341:319-327.
24. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888-1894.
25. Luciardi H, Berman S, Muntaner J, et al. Facilitated thrombolysis: dethrombosis? Clin Appl Thromb Hemost 2002; 8:133-138.
26. Tepe G, Schott U, Erley CM, et al. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral artery thrombosis. AJR Am J Roentgenol 1999; 172:1343-1346.
27. Duda SH, Tepe G, Luz O, et al. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone-a randomized pilot trial (the PROMPT study). Radiology 2001; 221:689-696.
28. Ouriel K, Castaneda F, McNamara T, et al. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial. J Vasc Interv Radiol 2004; 15:229-238.
29. Hull JE, Hull MK, Urso JA. Reteplase with or without abciximab for peripheral arterial occlusions: efficacy and adverse events. J Vasc Interv Radiol 2004; 15:543-546.
30. Meyerovitz M, Goldhaber SZ, Reagan K, et al. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology 1990; 175:75-78.